Core Insights - Tevogen Bio Holdings Inc. is expanding its collaboration with Microsoft and Databricks to develop the beta version of its PredicTcell model, focusing on oncology [1][7] - The initiative aims to enhance the accuracy of the PredicTcell model by curating a dataset that combines oncology and virology data [2][7] - The development is supported by a recently published international patent application outlining novel machine learning systems for predicting immunologically active peptides, crucial for targeted therapies [3] Company Developments - Tevogen.AI is leveraging the Databricks Data Intelligence Platform to improve its foundational AI model, which is particularly impactful in drug discovery for oncology [2][4] - The company plans to explore external market opportunities as a potential revenue source while enhancing analytics and visualization tools for its internal R&D teams [7] - The collaboration with Microsoft and Databricks has been highlighted as a significant advantage in building the alpha version of the AI model [4]

Core Insights - Tevogen Bio Holdings Inc. is expanding its artificial intelligence initiative, Tevogen.AI, in collaboration with Microsoft and Databricks to develop the beta version of the PredicTcell model [1][2] - The new dataset being curated focuses on oncology and aims to enhance the accuracy of the existing model, which previously utilized a virology dataset [2] - The development phase is supported by a recently published international patent application that details novel machine learning systems for predicting immunologically active peptides, crucial for targeted cancer therapies [3] Company Developments - Tevogen.AI is leveraging the Databricks Data Intelligence Platform to improve its foundational AI model, particularly in the complex field of oncology [2][4] - The company is also exploring external market opportunities as a potential revenue source, which may include enhanced analytics and visualization tools for the PredicTcell model [7] Strategic Collaborations - The collaboration with Microsoft and Databricks is highlighted as a significant advantage in building the alpha version of the AI model, emphasizing the importance of high-quality datasets in drug discovery [4]